Andres Gutierrez, MD, PhD is an experienced clinical scientist with a proven record of drug development of small molecules and biologics, regulatory filings and fundraising activities. This includes more than 18 years of global clinical development experience including optimization of strategic development, and oversight of scientific, clinical, regulatory and financial objectives for clinical programs in oncology. Andres served as Advaxis Executive Vice President and Chief Medical Officer prior to the merger with Ayala Pharmaceuticals. Before joining Advaxis, he served as Chief Medical Officer for Oncolytics Biotech, Inc. and Chief Medical Officer at SELLAS Life Sciences Group. Prior to these positions, he worked at several large and small biotechnology companies, including Bristol Myers Squibb, Sunesis Pharmaceuticals, BioMarin Pharmaceutical, Proteolix and Oculus Innovative Sciences, where he led key development programs with small molecules (e.g., carfilzomib, talazoparib, JAK2i), antibodies (e.g., nivolumab, ipilimumab, anti-LAG3 & CXCR4) and biologic agents (e.g., oncolytic viruses, adenoviral & Lm vectors). His work includes studies in phases 1- 4 in the US and abroad, and he has served in previous clinical and academic positions at large medical centers. Andres holds an MD and PhD in Biomedical Sciences from the National University of Mexico (UNAM), is board certified in internal medicine (UNAM-IMSS) and completed a fellowship in oncology (Hammersmith Hospital, London UK).